The dosing schedule in the phase II study was 15 mg/kg administered intravenously on day 1 and 8 of a 21-day cycle. Victor Villalobos, MD, PhD: The appropriate dosing for this, in the first-line setting or even in the second- and third-line setting, is to give doxorubicin on day 1 of every 21-day cycle at 75 mg/m2.